Faktor-Faktor Penyebab Kegagalan Penyedia Jasa pada Proses Evaluasi Penawaran Tender Konstruksi

Tender is a series of bidding activity processes that aim to select, obtain, determine, and designate the mostappropriate company to work on a work package. One of them is construction tenders, in which theconstruction industry has a very important role in the economic and social development of a nation. The tenderprocess can be attended by more than one participant, where these companies compete with each other to beable to win a work package. With too many companies, service providers need to have competitive offers inorder to get a positive result in order to win in project tenders. Only the best participant will be the winner inthis competition, so that other participants will be declared failed in the bidding process. This article aims tofind out what factors cause service provider failure in the evaluation process for construction tender bids sothat it becomes a means for self-introspection and finding the best solution that can somewhat minimize thefailure factor. This article uses a literature study method regarding the factors that cause service providerfailure in the process of evaluating construction tender bids by comparing several related journals and basedon current regulations. From the results of the literature study, it was found that there were 45 factors causingthe failure of service providers in the process of evaluating construction bids, which came from 3 previousresearch sources and 2 current regulations

PENGARUH DAYA TARIK, KREDIBILITAS, DAN KESESUAIAN ANTARA CELEBRITY DAN ATHLETE ENDORSER DENGAN PRODUK YANG DIMODELKAN TERHADAP PERILAKU PEMBELIAN KONSUMEN

Penelitian ini bertujuan untuk menguji dan membandingkan pengaruh daya tarik, kredibilitas dan kesesuaian antara selebritis dan atlet pendukung dengan produk yang dimodelkan terhadap perilaku pembelian konsumen. Subjek penelitian adalah mahasiswa Fakultas Ekonomi Universitas Atma Jaya Yogyakarta. Sedangkan objek penelitian adalah Fakultas Ekonomi Universitas Atma Jaya Yogyakarta. Teknik pengambilan sampel dilakukan dengan Purposive Sampling. Pengumpulan data dalam penelitian ini dilakukan dengan membagikan kuisioner pada 260 responden. Penelitian ini menggunakan alat analisis analisis regresi sederhana dan uji beda dengan bantuan program SPSS versi 16. Hasil penelitian menunjukkan bahwa daya tarik, kredibilitas dan kesesuaian antara selebritis dan atlet pendukung dengan produk yang dimodelkan berpengaruh positif terhadap perilaku pembelian konsumen. Selain itu, endorser atlet dianggap lebih kredibel dan sesuai untuk dijadikan endorser produk minuman berenergi

The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines

Anthracycline-induced cardiotoxicity typically presents as congestive heart failure (CHF). As immuno-inflammatory activation and apoptosis are important mechanisms in the process of heart failure, the use of biomarkers that could detect cardiovascular toxicity before the clinical presentation is of great importance. We studied whether sTNF-a, sTNF-RI, sTNF-RII, Fas/FasLigand system and NT-proBNP associate with early cardiac dysfunction in patients receiving cardiotoxic drugs. Two groups of breast cancer patients—group A with metastatic disease under chemotherapy with epirubicin and group B with no residual disease under a less cardiotoxic regimen—as well as healthy women were included in this prosprective study. NT-proBNP, sTNF-a, sTNF-RI, sTNF-RII, sFas, sFas-Ligand and left ventricular ejection fraction (LVEF) were determined in all patients before and after the completion of chemotherapy. In Group A, an increase in sFas levels (p < 0.001), a decrease in the sFasL levels (p = 0.010), an NT-proBNP increase (p < 0.001) and a significant reduction of LVEF (p < 0.001) was recorded post-chemotherapy. The decrease in LVEF correlated significantly with the increase in sFas, the decrease in sFasL and the rise in NT-proBNP levels. In Group B, TNF-RI levels were higher (p = 0.024) and mean sFas-L levels lower (p = 0.021) post chemotherapy with no LVEF drop. Two of group A (7.6%) patients developed symptomatic CHF 12 and 14 months respectively after the end of chemotherapy. SFas, sFas-L and NT-proBNP correlate with reductions in LVEF and could be used as sensitive biochemical indices for the detection of asymptomatic left ventricular dysfunction in cancer patients under cardiotoxic chemotherapy

Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease

Aims We investigated, in a 6 year follow-up study, whether circulating levels of C-reactive protein (CRP) and macrophage colony stimulating factor (MCSF) have an independent or complementary prognostic value in patients with chronic coronary artery disease (CAD). Methods and results MCSF and CRP were measured in 100 patients with chronic CAD. Of 95 (33%) patients, 31 who completed the 6 year follow-up presented adverse events (death, myocardial infarction, and unstable angina). In multivariabte analysis (including traditional risk factors and medications), the upper tertiles of MCSF ( &gt;= 814 pg/mL) and CRP (&gt;= 2.5 mg/L) levels were independently associated with a 13- and 6-fold increase in risk of events, respectively (P &lt; 0.01). Patients with combined high CRP and MCSF had a higher absolute risk of events than patients with elevated MCSF or CRP atone (75 vs. 59 vs. 32%, respectively, P &lt; 0.01). The mean event-free time was 39, 64, and 52 months in patients with elevated MCSF, elevated CRP, and their combination, respectively. Conclusion In patients with chronic CAD, the prognostic value of MCSF is independent and comptementary to that of CRR MCSF is a particularly useful prognostic marker when CRP levels are low, but also provides additional information concerning risk and time-course of events in patients with elevated CRP

Pharmacodynamic comparison of low-dose ticagrelor to low-dose prasugrel in patients with prior myocardial infarction: the ALTIC-2 study

Given that patients with prior myocardial infarction and features of high ischemic and low bleeding risk may benefit by extending dual antiplatelet therapy beyond 1 year, we aimed of assessing platelet reactivity provided by ticagrelor 60 mg bid versus prasugrel 5 mg od in 20 such patients participating in a randomized, crossover study. The primary end point of platelet reactivity at the end of the two treatment periods (by VerifyNow, in PRU) was significantly lower for ticagrelor (31.9 PRU [95% CI 12.3–51.4]) compared with prasugrel (132.1 PRU [111.9–152.3]) with a least squares mean difference of –100.2 PRU (72.1–128.3, P &amp;lt;.001). This dedicated pharmacodynamic study showed that in post-myocardial infarction patients with high atherothrombotic risk and receiving P2Y12 receptor antagonist beyond 1 year, low-dose ticagrelor results in a significantly lower platelet reactivity compared to low-dose prasugrel. © 2019 Taylor &amp; Francis Group, LLC

Pharmacodynamic comparison of low-dose ticagrelor to low-dose prasugrel in patients with prior myocardial infarction: the ALTIC-2 study

Given that patients with prior myocardial infarction and features of high ischemic and low bleeding risk may benefit by extending dual antiplatelet therapy beyond 1 year, we aimed of assessing platelet reactivity provided by ticagrelor 60 mg bid versus prasugrel 5 mg od in 20 such patients participating in a randomized, crossover study. The primary end point of platelet reactivity at the end of the two treatment periods (by VerifyNow, in PRU) was significantly lower for ticagrelor (31.9 PRU [95% CI 12.3–51.4]) compared with prasugrel (132.1 PRU [111.9–152.3]) with a least squares mean difference of –100.2 PRU (72.1–128.3, P < .001). This dedicated pharmacodynamic study showed that in post-myocardial infarction patients with high atherothrombotic risk and receiving P2Y12 receptor antagonist beyond 1 year, low-dose ticagrelor results in a significantly lower platelet reactivity compared to low-dose prasugrel

The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines

Background: Anthracycline-induced cardiotoxicity typically presents as congestive heart failure (CHF). As immuno-inflammatory activation and apoptosis are important mechanisms in the process of heart failure, the use of biomarkers that could detect cardiovascular toxicity before the clinical presentation is of great importance. We studied whether sTNF-a, sTNF-RI, sTNF-RII, Fas/FasLigand system and NT-proBNP associate with early cardiac dysfunction in patients receiving cardiotoxic drugs. Methods: Two groups of breast cancer patients-group A with metastatic disease under chemotherapy with epirubicin and group B with no residual disease under a less cardiotoxic regimen-as well as healthy women were included in this prosprective study. NT-proBNP, sTNF-a, sTNF-RI, sTNF-RII, sFas, sFas-Ligand and left ventricular ejection fraction (LVEF) were determined in all patients before and after the completion of chemotherapy. Results: In Group A, an increase in sFas levels (p< 0.001), a decrease in the sFasL levels (p= 0.010), an NT-proBNP increase (p < 0.001) and a significant reduction of LVEF (p< 0.001) was recorded post-chemotherapy. The decrease in LVEF correlated significantly with the increase in sFas, the decrease in sFasL and the rise in NT-proBNP levels. In Group B, TNF-RI levels were higher (p= 0.024) and mean sFas-L levels lower (p= 0.021) post chemotherapy with no LVEF drop. Two of group A (7.6%) patients developed symptomatic CHF 12 and 14. months respectively after the end of chemotherapy. Conclusion: SFas, sFas-L and NT-proBNP correlate with reductions in LVEF and could be used as sensitive biochemical indices for the detection of asymptomatic left ventricular dysfunction in cancer patients under cardiotoxic chemotherapy. © 2015 The Authors. Published by Elsevier Ireland Ltd

IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease

Background: Circulating anticardiolipin antibodies (aCL) may cause endothelial dysfunction. We investigated whether aCL are related to platelet activation, thrombin generation and daily-life ischaemia in patients with chronic coronary artery disease (CAD). Methods: We measured (medians 25th-75th percentile) IgG, IgM, IgA aCL serum levels (Arbitrary Elisa Units, AEU), prothrombin fragments (F1+2, nmol/l), 24 h urine excretion of 11-dehydrothromboxane B2 (11-DHTXB2, ng/mg creatinine) creatine kinase (CK) and its cardiac isoenzyme CK-MB (IU/I) in 60 patients with angiographically documented CAD and in 40 age and sex matched controls. Patients underwent a 48 h Holter monitoring for assessment of the number and duration of ischaemic episodes. Results: Patients had higher IgA-aCL levels than controls (3.2 vs 2.4 AEU, p = 0.002). Increased IgA-ACA levels were related to increased number and duration of ischaemic episodes (p&lt;0.01). By ANOVA, patients with ≥10 ischaemic episodes (3rd fertile) or duration of ischaemia ≥32min (3rd fertile) had higher IgA-aCL than those with lower ischaemic burden (4.95 vs 3 vs 2.5 AEU, p = 0.002 and 4.9 vs 3 vs 2.5 AEU, p = 0.001 respectively). Patients with ≥2 ischaemic episodes (2nd and 3rd fertile) had higher 11-DHTXB2, than those with minimal ischaemia (2&lt; episodes, 1st tertile) (p = 0.001). CK and CK-MB were within normal range after Holter monitoring. Receiver operating curve analysis showed a greater area under the curve for IgA-aCL than for 11-DHTXB2 in predicting severe ischaemia ≥10 ischemic episodes or ≥32 min duration of ischaemia). Conclusion: Increasing IgA-aCL levels are associated with increasing ischemic burden in patients with CAD